Today, it's a fairly commonplace procedure.
"It is a certainty that in five to 10 years, this is going to be the standard of care," O'Connell said.
The technology, which sequences DNA and RNA quickly and cheaply, will help doctors customize their treatment to specific conditions, O'Connell said.
"That is going to enable clinicians to be very precise in the measures they take the fight the illness, which is especially true in pediatrics and oncology," he said. "It is something we are busy working on."
For now though, O'Connell said, it's difficult to say how many workers will employed by
It is already widely covered by insurance in
"Right now we are kind of at the nexus," O'Connell said. "I'm not sure when this thing will move into the standard reimbursement model, but I know that it will. We very much hope to be one of the major players in
B. Braun and Tubingen-based CeGat announced their partnership last week, saying it will be headquartered at B. Braun's headquarters building in
While it's use is fairly common in pre-natal situations, insurance companies typically pay for diagnostic genetic testing only when it meets four criteria, said
There must be a clinical basis to suspect a specific disease, a valid test to detect that disease and a treatment if the test comes back positive. The fourth condition is that the patient must agree to undergo genetic counseling.
The prevalent form of genetic testing now in use is called the Sanger method, O'Connell said, and it's what most insurers are willing to pay for.
But a variety of companies have developed next-generation sequencing technologies for a wide range of clinical and research applications that perform the testing more quickly and comprehensively than the Sanger method. It's a rapidly growing industry.
According to the life sciences consulting firm Deci Bio, the market for next generation sequencing is the fastest growing segment of the
"NGS is poised to revolutionize not only medical research in academic laboratories and Biopharma, but also the health care landscape," the firm said in a
For now in the U.S., B. Braun CeGaT is working with disease foundations to cover the cost of limited next generation genomic sequencing of patients with neuromuscular and epilepsy-related conditions, a procedure that typically costs thousands of dollars.
The launch of a new company on the cutting edge of genetic diagnostics was cheered
"It's good news for
The new venture joins parent company
(c)2014 The Morning Call (Allentown, Pa.)
Visit The Morning Call (Allentown, Pa.) at www.mcall.com
Distributed by MCT Information Services